{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:44:10Z","timestamp":1793335450184,"version":"4.5.0"},"reference-count":99,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,4,12]]},"DOI":"10.1001\/jama.2022.4402","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T16:58:16Z","timestamp":1649782696000},"page":"1379","source":"Crossref","is-referenced-by-count":633,"title":["Diagnosis and Treatment of Pulmonary Arterial Hypertension"],"prefix":"10.1001","volume":"327","author":[{"given":"Nicole F.","family":"Ruopp","sequence":"first","affiliation":[{"name":"Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Cockrill","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"jrv220007r1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry.","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"1","key":"jrv220007r2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01904-2018","article-title":"Diagnosis of pulmonary hypertension.","volume":"53","author":"Frost","year":"2019","journal-title":"Eur Respir J"},{"issue":"5","key":"jrv220007r3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective registry.","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"1","key":"jrv220007r4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension.","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv220007r5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension.","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"13","key":"jrv220007r6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking program.","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"jrv220007r7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.mcna.2018.12.002","article-title":"Pulmonary hypertension.","volume":"103","author":"Kim","year":"2019","journal-title":"Med Clin North Am"},{"issue":"3","key":"jrv220007r8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension.","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv220007r9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","article-title":"Pulmonary vascular remodeling in pulmonary hypertension.","volume":"367","author":"Tuder","year":"2017","journal-title":"Cell Tissue Res"},{"issue":"6","key":"jrv220007r10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/S0735-1097(02)02964-9","article-title":"Pulmonary function in primary pulmonary hypertension.","volume":"41","author":"Sun","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv220007r11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.","volume":"53","author":"Vonk Noordegraaf","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"jrv220007r12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry.","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv220007r13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension: a national prospective study.","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"issue":"25","key":"jrv220007r14","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries.","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"jrv220007r15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL registry.","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"issue":"7","key":"jrv220007r16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension.","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv220007r17","first-page":"194","article-title":"Familial primary pulmonary hypertension: clinical patterns.","volume":"129","author":"Loyd","year":"1984","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"jrv220007r18","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jacc.2009.04.015","article-title":"Genetics and genomics of pulmonary arterial hypertension.","volume":"54","author":"Machado","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv220007r19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension.","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"issue":"12","key":"jrv220007r20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/jmg.40.12.865","article-title":"Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.","volume":"40","author":"Harrison","year":"2003","journal-title":"J Med Genet"},{"issue":"12","key":"jrv220007r21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1164\/rccm.200712-1807OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.","volume":"177","author":"Sztrymf","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"jrv220007r22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.","volume":"181","author":"Girerd","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv220007r23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.201705-0943OC","article-title":"Features and outcomes of methamphetamine-associated pulmonary arterial hypertension.","volume":"197","author":"Zamanian","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"jrv220007r24","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis.","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"17","key":"jrv220007r25","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib.","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"jrv220007r26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension.","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"jrv220007r27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"jrv220007r28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv220007r29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"issue":"3","key":"jrv220007r30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study.","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"jrv220007r31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/diagnostics11050911","article-title":"Systemic sclerosis-associated pulmonary hypertension: spectrum and impact.","volume":"11","author":"Naranjo","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"jrv220007r32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv220007r33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1164\/rccm.200704-541OC","article-title":"Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.","volume":"177","author":"Sitbon","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv220007r34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors.","volume":"178","author":"Le Pavec","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv220007r35","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/(ISSN)1527-3350","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm.","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"jrv220007r36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-0032-1301731","article-title":"Portopulmonary hypertension.","volume":"33","author":"Krowka","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"issue":"2","key":"jrv220007r37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.v73.2","article-title":"Estrogen signaling and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).","volume":"73","author":"Al-Naamani","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"jrv220007r38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/hep.v59.3","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"jrv220007r39","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/hep.28990","article-title":"Long-term outcome in liver transplantation candidates with portopulmonary hypertension.","volume":"65","author":"Savale","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"jrv220007r40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"jrv220007r41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/eurheartj\/eht072","article-title":"Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease.","volume":"35","author":"Manes","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"jrv220007r42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00019501-200502000-00004","article-title":"The remarkable right ventricle of patients with Eisenmenger syndrome.","volume":"16","author":"Hopkins","year":"2005","journal-title":"Coron Artery Dis"},{"issue":"6","key":"jrv220007r43","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.1378\/chest.10-0048","article-title":"Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.","volume":"137","author":"Graham","year":"2010","journal-title":"Chest"},{"key":"jrv220007r44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608883","article-title":"Schistosomiasis pulmonary arterial hypertension.","volume":"11","author":"Sibomana","year":"2020","journal-title":"Front Immunol"},{"key":"jrv220007r45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fimmu.2019.00027","article-title":"The role of type 2 inflammation in Schistosoma-induced pulmonary hypertension.","volume":"10","author":"Mickael","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"jrv220007r46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.pt.2019.11.007","article-title":"Clinical and preclinical imaging of hepatosplenic schistosomiasis.","volume":"36","author":"Masi","year":"2020","journal-title":"Trends Parasitol"},{"issue":"23","key":"jrv220007r47","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"jrv220007r48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1164\/rccm.201508-1678OC","article-title":"Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension.","volume":"194","author":"Hemnes","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv220007r49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv220007r50","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/01.pas.0000209834.69972.e5","article-title":"Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.","volume":"30","author":"Lantu\u00e9joul","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"jrv220007r51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MD.0b013e31818193bb","article-title":"Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.","volume":"87","author":"Montani","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"jrv220007r52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1378\/chest.113.1.237","article-title":"Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.","volume":"113","author":"Palmer","year":"1998","journal-title":"Chest"},{"issue":"2","key":"jrv220007r53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1378\/chest.13-2366","article-title":"EIF2AK4 mutations in pulmonary capillary hemangiomatosis.","volume":"145","author":"Best","year":"2014","journal-title":"Chest"},{"issue":"3","key":"jrv220007r54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ppul.v56.3","article-title":"Persistent pulmonary hypertension of the newborn.","volume":"56","author":"Mandell","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"jrv220007r55","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1165","article-title":"Persistent pulmonary hypertension of the newborn in late preterm and term infants in California.","volume":"139","author":"Steurer","year":"2017","journal-title":"Pediatrics"},{"issue":"1","key":"jrv220007r56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1378\/chest.10-1166","article-title":"Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry.","volume":"140","author":"Brown","year":"2011","journal-title":"Chest"},{"issue":"2","key":"jrv220007r58","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1378\/chest.122.2.524","article-title":"Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease.","volume":"122","author":"Ahearn","year":"2002","journal-title":"Chest"},{"issue":"5","key":"jrv220007r59","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1183\/09031936.00089610","article-title":"A noninvasive algorithm to exclude pre-capillary pulmonary hypertension.","volume":"37","author":"Bonderman","year":"2011","journal-title":"Eur Respir J"},{"issue":"6","key":"jrv220007r60","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.chest.2019.12.037","article-title":"Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension.","volume":"157","author":"Simpson","year":"2020","journal-title":"Chest"},{"key":"jrv220007r61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100568","article-title":"Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension.","volume":"29","author":"Ullah","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"12","key":"jrv220007r62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033084","article-title":"Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension.","volume":"9","author":"Ni","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"jrv220007r63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.echo.2015.11.001","article-title":"Addressing the controversy of estimating pulmonary arterial pressure by echocardiography.","volume":"29","author":"Amsallem","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"jrv220007r64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1751-7133.2010.00202.x","article-title":"REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension.","volume":"17","author":"Farber","year":"2011","journal-title":"Congest Heart Fail"},{"issue":"13","key":"jrv220007r65","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009362","article-title":"Lack of a tricuspid regurgitation Doppler signal and pulmonary hypertension by invasive measurement.","volume":"7","author":"O\u2019Leary","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"jrv220007r66","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1183\/09031936.00184412","article-title":"Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension.","volume":"42","author":"Trip","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv220007r67","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.chest.2020.01.046","article-title":"Outcomes of pulmonary arterial hypertension are improved in a specialty care center.","volume":"158","author":"Pi","year":"2020","journal-title":"Chest"},{"issue":"12","key":"jrv220007r68","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.jacc.2006.07.061","article-title":"Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers.","volume":"48","author":"Hoeper","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"jrv220007r69","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"jrv220007r70","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension.","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv220007r71","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension.","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv220007r72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension.","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"jrv220007r73","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension.","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"jrv220007r74","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"22","key":"jrv220007r75","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"jrv220007r76","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"jrv220007r77","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"issue":"9288","key":"jrv220007r78","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension.","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"jrv220007r79","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv220007r80","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv220007r81","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv220007r82","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv220007r83","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"issue":"2","key":"jrv220007r84","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"issue":"9630","key":"jrv220007r85","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study).","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"jrv220007r86","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study).","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"3","key":"jrv220007r87","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study).","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"issue":"8","key":"jrv220007r88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension.","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"issue":"11","key":"jrv220007r89","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"jrv220007r90","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension.","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"jrv220007r91","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension.","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"jrv220007r92","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertens Res"},{"issue":"142","key":"jrv220007r93","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1183\/16000617.0085-2016","article-title":"Beyond a single pathway: combination therapy in pulmonary arterial hypertension.","volume":"25","author":"Sitbon","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"3","key":"jrv220007r94","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report.","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"issue":"7","key":"jrv220007r95","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/bph.v177.7","article-title":"Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.","volume":"177","author":"Maron","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"4","key":"jrv220007r96","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1164\/arrd.1985.131.4.493","article-title":"Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.","volume":"131","author":"Weitzenblum","year":"1985","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"jrv220007r97","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1086\/682230","article-title":"Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.","volume":"5","author":"Hemnes","year":"2015","journal-title":"Pulm Circ"},{"issue":"4","key":"jrv220007r98","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1183\/09031936.00141211","article-title":"Pregnancy outcomes in pulmonary arterial hypertension in the modern management era.","volume":"40","author":"Ja\u00efs","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"jrv220007r99","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1086\/674312","article-title":"Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension.","volume":"3","author":"Fessel","year":"2013","journal-title":"Pulm Circ"},{"key":"jrv220007r57","first-page":"339","volume-title":"Brigham Intensive Review of Internal Medicine","author":"Wertheim","year":"2017","edition":"3rd ed"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2790933\/jama_ruopp_2022_rv_220007_1662040577.72953.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:54:16Z","timestamp":1662479656000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2790933"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":99,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.4402","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}